Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilparencel - inRegen

Next Previous
Drug Profile

Rilparencel - inRegen

Alternative Names: Autologous cultured kidney tissue cells - inRegen; Autologous cultured kidney tissue cells - Tengion; Autologous Neo-Kidney augment; Neo-Kidney Augment; Neo-kidney-augment; NKA; ReACT; REACT™; Regenerative autologous cell therapy; Renal Autologous Cell Therapy

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tengion
  • Developer inRegen; ProKidney
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Kidney disorders; Type 2 diabetes mellitus
  • No development reported Renal failure

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for phase-I development in Kidney-disorders(In the elderly, Treatment-experienced, In adults) in USA (Transdermal, Injection)
  • 19 Mar 2026 ProKidney anticipate BLA approval and commercial launch of Rilparencel in second quarter of 2028
  • 19 Mar 2026 ProKidney anticipate BLA submission of Rilparencel in fourth quarter of 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top